Stocks · News reference
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
Micron and 15 Other Stocks To Play The AI Buildout Race: They Are Still 20% Below Highs
Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.